Select publications

Baselga J et al. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 2004;31(5 Suppl 10):51-7. Abstract

Bell R et al. Maximizing clinical benefit with trastuzumab. Semin Oncol 2004;31(5 Suppl 10):35- 44. Abstract

Blum JL et al. ABI-007 nanoparticle paclitaxel: Demonstration of anti-tumor activity in taxane-refractory metastatic breast cancer. Presentation. ASCO 2004;Abstract 543.

Emens LA, Davidson NE. Trastuzumab in breast cancer. Oncology (Huntingt) 2004;18(9):1117-28. Abstract

Geyer, CE Jr et al. Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus trastuzumab in patients (pts) with operable, nodepositive (N+), HER-2 overexpressing breast cancer (HER2+BC). San Antonio Breast Cancer Symposium 2003;Abstract 23.

O’Shaughnessy J et al. ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs Taxol in MBC: A phase III trial. Presentation. San Antonio Breast Cancer Symposium 2003;Abstract 44.

O’Shaughnessy JA et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in longterm disease control in patients with taxane-refractory metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 1070.

Perez E. Presentation. Miami Breast Cancer Conference 2005. No abstract available Perez EA et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004;22(18):3700-4. No abstract available

Perez EA et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. Proc ASCO 2005;Abstract 556.